New pill shows promise for tough blood cancers
NCT ID NCT05732103
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called CTX-712 in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to treatment. The drug is taken by mouth once or twice weekly. The trial aims to find the safest dose and see if it can shrink or control the cancer. About 225 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX-712 (an experimental oral drug taken once or twice weekly)
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat AML or MDS, potentially helping control the disease.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 225 participants, so the drug may not work or could have serious side effects. It is not a cure and long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic Comprehensive Cancer Center
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-••••
Contact
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact